Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer

 Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer

Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer

Shots:
  • The P-III NALA Trial involves assessing of Neratinib + capecitabine vs Tykerb (lapatinib) + capecitabine in 621 patients in ratio (1:1) with HER2-Positive Metastatic Breast Cancer
  • The P-III NALA Trial demonstrated improvement in PFS by 1% and OS by 4% with safety profile consistent with previous trials
  • Neratinib is an irreversible tyrosine kinase inhibitor, or TKI used for blocking signal transduction through EGFRs, HER1, HER2 and HER4, approved by the US FDA for early stage HER2-overexpressed/amplified breast cancer in adults

Click here to read full press release/ article | Ref: Puma Biotechnology | Image: Pharmaphorum

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post